Copertina

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jiahao Liu, Yang Fu
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
di: Walter W. Chan, et al.
Pubblicazione: (2026)

Letter: H. pylori Infection May Constitute a Risk Factor for Reflux Disease and Colonic Neoplasia
di: Jannis Kountouras, et al.
Pubblicazione: (2025)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease
di: Javier Chahuán, et al.
Pubblicazione: (2026)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
di: Brigida Barberio, et al.
Pubblicazione: (2026)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
di: Finlay Macrae
Pubblicazione: (2025)

Editorial: The Milan Score as Supportive Evidence of Gastro‐Oesophageal Reflux Disease. Authors' Reply
di: Stefano Siboni, et al.
Pubblicazione: (2026)

Research Communication: Reflux Disease May Constitute a Risk Factor for Colonic Neoplasia
di: Amnon Sonnenberg, et al.
Pubblicazione: (2025)

Integrated Analysis of Vonoprazan Safety for Symptomatic Gastro‐Oesophageal Reflux Disease or Erosive Oesophagitis
di: Colin W. Howden, et al.
Pubblicazione: (2024)

Review Article: Individualised Management of Reflux‐Like Symptoms—Strategies Beyond Acid Suppression
di: Peter J. Kahrilas, et al.
Pubblicazione: (2025)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
di: Chunlong Liu, et al.
Pubblicazione: (2025)

Letter: From Descriptive Epidemiology to Clinical Imperative—Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease
di: DuJiang Yang, et al.
Pubblicazione: (2025)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
di: Emmanuel Pio Pastore
Pubblicazione: (2025)

Letter: Methodological Flaws and Clinical Gaps—A Critique of TAF / TDF 5‐Year Data in East Asian CHB
di: Zhiyao Shi, et al.
Pubblicazione: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
di: Leyu Zhou, et al.
Pubblicazione: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
di: Abdulrahman Ismaiel
Pubblicazione: (2026)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
di: Xueneng Yang, et al.
Pubblicazione: (2025)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
di: Liang Jiao, et al.
Pubblicazione: (2026)

Letter: FIT ‐Based Triage for Symptomatic Colonoscopy‐Diagnostic Yield Is Not the Same as Pathway Safety
di: Stjepan Škudar
Pubblicazione: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Editorial: Distinct Challenges of Paediatric From Adult‐Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children
di: Alessandro Molinaro, et al.
Pubblicazione: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
di: Chang Liu, et al.
Pubblicazione: (2026)

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
di: Xing Bai, et al.
Pubblicazione: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
di: Muhammad Osama, et al.
Pubblicazione: (2024)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
di: Kuan‐Ju Lin, et al.
Pubblicazione: (2025)

Use of a Non‐Endoscopic Capsule‐Sponge Triage Test for Reflux Symptoms: Results From the NHS England Prospective Real‐World Evaluation
di: Vlasios Gourgiotis, et al.
Pubblicazione: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
di: Luis Antonio Díaz, et al.
Pubblicazione: (2025)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
di: Rónán O'Connor, et al.
Pubblicazione: (2026)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
di: Rong‐Xiang Ng, et al.
Pubblicazione: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
di: Nina Dominik, et al.
Pubblicazione: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
di: Ziheng Calvin Xu, et al.
Pubblicazione: (2025)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
di: Yan Liu, et al.
Pubblicazione: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
di: Qiong Yi, et al.
Pubblicazione: (2024)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
di: Cong Dai, et al.
Pubblicazione: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
di: Xinli Chen, et al.
Pubblicazione: (2024)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Stergios A. Polyzos, et al.
Pubblicazione: (2024)